GWM
KYTX icon

GSB Wealth Management’s Kyverna Therapeutics KYTX Stock Holding History

GSB Wealth Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$68K Hold
10,000
– – 0.01% 237
2026
Q2 		$89.1K Hold
10,000
– – 0.02% 234
2026
Q1 		$86.3K Buy
+10,000
New +$83.3K 0.02% 223

Other funds holding KYTX

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Propel Bio Management
Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

GSB Wealth Management's KYTX Position: Q3 2026 in Review

GSB Wealth Management held its Kyverna Therapeutics (KYTX) position steady in Q3 2026 at 10,000 shares worth $68K. The position accounts for 0.01% of the portfolio, ranked #237.

GSB Wealth Management first reported a position in KYTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $89.1K in Q2 2026. 82 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

  • GSB Wealth Management held 10,000 shares of Kyverna Therapeutics worth $68K as of Q3 2026.
  • GSB Wealth Management left its Kyverna Therapeutics share count unchanged in Q3 2026.
  • Kyverna Therapeutics made up 0.01% of GSB Wealth Management's portfolio in Q3 2026, its #237 holding.
  • GSB Wealth Management first reported a position in Kyverna Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • GSB Wealth Management's Kyverna Therapeutics position peaked at $89.1K in Q2 2026.
  • 82 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on GSB Wealth Management's 13F filing for Q3 2026, filed 2 Nov 2026.